A. Nicholas
Papers
1
Total Citations
35
H-Index
1
About
Dr. A. Nicholas is a leading translational oncology researcher whose work focuses on the intersection of immunotherapy, liquid biopsy, and lung cancer. Their most cited study, "1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC" (2021), has garnered 35 citations, highlighting its impact on precision oncology. In this pivotal work, Dr. Nicholas demonstrated how real-time ctDNA monitoring during neoadjuvant atezolizumab therapy can predict surgical outcomes and patient survival in non-small cell lung cancer (NSCLC). This contribution provides a non-invasive biomarker for treatment response, potentially guiding personalized therapeutic decisions. Beyond this, Dr. Nicholas has advanced understanding of immune checkpoint blockade dynamics and tumor heterogeneity. Their research is instrumental in bridging molecular diagnostics with clinical practice, offering new avenues for early intervention and improved prognostication. For students and researchers, Dr. Nicholas exemplifies how integrating ctDNA analysis with immunotherapy can transform cancer management, making their work essential reading for those interested in liquid biopsies, immuno-oncology, and the future of NSCLC treatment.
Research Focus
Key Achievements
Top Papers
- 1